Wednesday, 16 Oct 2019

You are here

Turnabout for Baricitinib

Eli Lilly and Company and Incyte Corporation announced today that, after discussions with the U.S. Food and Drug Administration (FDA) in late August 2017, Lilly will resubmit a revised New Drug Application (NDA) for baricitinib before the end of January 2018. The resubmission package will include new safety and efficacy data.  

The resubmission will address the FDA's July 2017 concerns about safety, especially the "imbalance in thromboembolic events" only seen with the 4 mg dose, during the placebo-controlled period of the rheumatoid arthritis (RA) development trials. 

The companies anticipate the FDA will classify the application as a Class II resubmission, which will start a new six-month review cycle. This is a dramatic change from prior projections that anticipated an 18 month delay in resubmission and a projected drug launch in 2021. 

Baricitinib is a once-daily oral investigational medication for the treatment of patients with moderate-to-severe RA. Baricitinib is a potential competitor to Pfizer's Xeljanz (tofacitinib), whose sales are up more than 40% and project to be greater than $1 billion in 2017. In development are two other Jak inhibitors: filgotinib (Gilead Sciences) and upadacitinib (AbbVie). 

It remains to be seen if the 2 mg or 4 mg dose (or both) will be accepted by the FDA for safe use.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Biologics Lead the Way in Drug Price Increases

Reuters has reported the results of a recent Institute for Clinical and Economic Review (ICER) analysis showing that biologics, especially Humira and Rituxan, are leading the way in the cost of drugs in the USA. All told, Humira and Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. drug spending. ICER said their analysis points to price hikes that were more than twice the rate of medical inflation and were not warranted by any new clinical evidence.

Ustekinumab Efficacy in Ulcerative Colitis

The NEJM reports the results of a one year trial wherein ustekinumab (UST) was shown to be effective at inducing and maintaining remission in patients with moderate-to-severe ulcerative colitis. Ustekinumab, currently approved for use in psoriasis, psoriatic arthritis and Crohn's disease, is a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23.

FDA Approves Rituximab for Children with GPA

The U.S. Food and Drug Administration has approved Rituxan (rituximab) for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination with glucocorticoids. This is the first approved treatment for children with vasculitis.

Anakinra Shows Benefits in Cytokine Storm

The interleukin (IL)-1 receptor antagonist anakinra (Kineret) showed promise in critically ill children who develop the often-lethal condition known as secondary hemophagocytic lymphohistiocytosis (sHLH)/macrophage activation syndrome (MAS), a retrospective single-center study found.

 

Prior Authorizations Delay Care in Rheumatology

Physicians who believe their patients' health is negatively affected by insurers' demands for prior authorization, and the delays that often result, will find that opinion vindicated by a new study of rheumatology care: when permission had to be sought from insurers to provide intravenous drugs, average time to begin treatment was longer and patients had twice the corticosteroid exposure, a single-center analysis found.